Thursday, June 06, 2024 7:23:41 AM
Over $6
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent VNDA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 08:49:38 PM
- Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences • PR Newswire (US) • 05/07/2026 10:44:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:01:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:06:17 PM
- Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/06/2026 08:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2026 04:15:14 AM
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years • PR Newswire (US) • 05/01/2026 08:35:00 PM
- Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 • PR Newswire (US) • 04/29/2026 08:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/29/2026 08:08:37 PM
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence • PR Newswire (US) • 04/28/2026 11:12:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 08:35:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:50:50 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:48:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 09:23:06 PM
- Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors • PR Newswire (US) • 04/22/2026 09:13:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:38:37 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:37:04 PM
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines • PR Newswire (US) • 04/09/2026 03:02:00 PM
- Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists • PR Newswire (US) • 04/08/2026 08:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:30:32 PM
- Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods • PR Newswire (US) • 03/19/2026 08:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:54:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:51:51 PM
